Lung Injury Associated with Bortezomib Therapy in Relapsed/Refractory Multiple Myeloma in Japan:

DOI Web Site PubMed 2 Citations 17 References
  • GOTOH Akihiko
    The “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology
  • OHYASHIKI Kazuma
    The “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology
  • OSHIMI Kazuo
    The “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology
  • USUI Noriko
    The “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology
  • HOTTA Tomomitsu
    The “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology
  • DAN Kazuo
    The “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology
  • IKEDA Yasuo
    The “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology

Bibliographic Information

Other Title
  • 日本における再発・難治性多発性骨髄腫に対する個人輸入ボルテゾミブ治療に関連した肺障害
  • 臨床研究 日本における再発・難治性多発性骨髄腫に対する個人輸入ボルテゾミブ治療に関連した肺障害--日本血液学会・日本臨床血液学会アンケート調査に基づく「ボルテゾミブ肺障害調査委員会」よりのレポート
  • リンショウ ケンキュウ ニホン ニ オケル サイハツ ナンジセイ タハツセイ コツズイシュ ニ タイスル コジン ユニュウ ボルテゾミブ チリョウ ニ カンレン シタ ハイ ショウガイ ニホン ケツエキ ガッカイ ニホン リンショウ ケツエキ ガッカイ アンケート チョウサ ニ モトヅク ボルテゾミブ ハイ ショウガイ チョウサ イインカイ ヨリ ノ レポート
  • ―日本血液学会・日本臨床血液学会アンケート調査に基づく「ボルテゾミブ肺障害調査委員会」よりのレポート―
  • A Questionnaire-based Report from the “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology

Search this article

Abstract

Bortezomib is a proteasome inhibitor that can be effective in the treatment of refractory and relapsed multiple myeloma. Recently, severe pulmonary complications associated with bortezomib therapy have been reported in Japan. Because bortezomib has not yet been approved for general use in Japan and is imported by attending physicians on the request of patients, The Japanese Society of Hematology and The Japanese Society of Clinical Hematology sent urgent questionnaires to the councilors of both societies in order to explore the situation and details of pulmonary complications associated with bortezomib therapy. Clinical details were available for 46 patients who had been treated with personally imported bortezomib in Japan. Seven patients (15.2%), including 3 who died from respiratory failure, showed complications definitely or probably caused by bortezomib. Of the 7 patients, 6 had a prior history of stem cell transplantation (SCT), whereas only 14 of 39 patients without lung injury had received SCT treatment (p=0.033 by Fischer's exact test). Multivariate analysis revealed that the concomitant use of corticosteroids might reduce the risk of lung injury (p=0.024; odds ratio=0.055) and that a previous SCT might increase the risk (p=0.042; odds ratio=13.140). We summarized these data from questionnaires for a limited Japanese cohort and therefore do not know the precise incidence of lung injury linked to fatal progression. Thus, future verification concerning these matters is warranted after the approval of bortezomib for use in Japan. Clinicians should be aware of the possibility of severe pulmonary complications associated with bortezomib therapy.<br>Note that this report has the same contents as the article appeared in the International Journal of Hematology (vol. 84, p406∼412, 2006) by permission of both the editorials of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology, and should be considered as the Japanese translation of the article.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 47 (12), 1521-1527, 2006

    The Japanese Society of Hematology

Citations (2)*help

See more

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top